Pfizer Extends Commitment to Help Unemployed Americans

Pfizer Inc.Pfizer will extend its MAINTAIN™ (Medicines Assistance for Those who Are in Need) patient assistance program for an additional year, through December 31, 2010. In addition to the more than 70 Pfizer primary care medicines currently available through MAINTAIN, Pfizer will extend the benefits of MAINTAIN to many legacy Wyeth medicines.

Pfizer launched MAINTAIN in May to help unemployed and uninsured Americans stay on their Pfizer medicines. The program, an employee-driven initiative, is part of Pfizer Helpful Answers®, Pfizer's family of patient assistance programs that helps uninsured and underinsured Americans get Pfizer medicines for free or at a savings. Seventy-five percent of people who have applied to Pfizer’s MAINTAIN program have been enrolled.

Coupled with testimonials from MAINTAIN members and other interactive features, Pfizer released the MAINTAIN widget, an online tool that guides users through a short series of questions that determine whether they may be eligible for MAINTAIN or for another Pfizer patient assistance program.

Gail Grime, a MAINTAIN member from Ohio, lost her employment and health insurance after a 23-year career working for a U.S.-based auto parts manufacturer. Ms. Grime learned about MAINTAIN in a newspaper article, which she has subsequently shared with her family and many of her former co-workers.

"When I lost my job, I found myself without medical coverage for the first time in years. But thanks to MAINTAIN, I don't have to cut back on my Pfizer medicines, or go without them," Ms. Grime said. "The application was easy but, most importantly, the folks in customer service answered every one of my questions. In these rough times, it’s nice to have someone looking out for you."

By extending the benefits of the MAINTAIN program for another year and to patients needing help with legacy Wyeth medicines, Pfizer is responding to the continued economic challenges facing hard-working Americans. Although the economy appears to be on the mend and the number of job losses has begun to slow, data show that unemployment remains at a 26-year high.

"In the last year, we have witnessed a great deal of suffering. Yet, our families, friends and neighbors have exhibited true American spirit, finding innovative ways to manage during tough times," said Jorge Puente, Pfizer's regional president of Worldwide Pharmaceuticals and a leading champion of the initiative. "Signs are pointing to recovery; however, millions of people are struggling without the benefit of insurance and without a regular income. As the world's largest biopharmaceutical company, we believe we have a corporate responsibility to help our fellow Americans who need the medicines Pfizer offers, but who do not have insurance to help pay for them. By extending MAINTAIN, we are hopeful that we can continue to relieve some of the burden created by the recession."

Pfizer has long been a leader in making medicines accessible to uninsured Americans, and MAINTAIN is just the latest example of Pfizer's innovation in the area of improved access. In 2004, the company expanded Pfizer Helpful Answers, the company's family of patient assistance programs, becoming the first pharmaceutical company to help anyone in the United States without prescription insurance, no matter their age or income.

Pfizer Helpful Answers has been helping uninsured and underinsured patients get Pfizer medicines for free or at a savings for more than two decades. In the last five years alone, Pfizer has helped more than 5 million uninsured patients get access to more than 51 million Pfizer prescriptions valued at more than $4.8 billion at wholesale cost through its patient assistance programs. The reach of Pfizer's patient assistance programs in each state is illustrated in one of the charts accompanying this release.

"Pfizer MAINTAIN is a response to the evolving needs of uninsured Americans. Access programs are, simply put, ingrained in our corporate culture," Puente said.

MAINTAIN Eligibility Requirements and Application
The MAINTAIN program has four eligibility requirements. Applicants must:

  • Be able to demonstrate loss of employment on or after January 1, 2009;
  • Lack prescription coverage;
  • Attest to financial need; and,
  • Have been on their Pfizer medicine for at least three months prior to unemployment and enrolling in the program.

The program is user-friendly, with a one-page application that Pfizer will typically process within two to three weeks. Applicants may download the one-page application from www.PfizerHelpfulAnswers.com, or request one by calling 866-706-2400, where live operators can help callers find out if they may be eligible for one of Pfizer's patient assistance programs.

The program will accept applications through December 31, 2010. If eligible for MAINTAIN, patients can get their medicines for free for up to one year after enrollment or until they become insured, whichever comes first. People who are uninsured and still need help after being on MAINTAIN for a year can apply to one of Pfizer's other patient assistance programs.

For Help with Wyeth Medicines
As a result of Pfizer and Wyeth coming together, Pfizer is also extending the benefits of MAINTAIN to people who need help staying on their Wyeth primary care medicines. Until the Pfizer and Wyeth patient assistance programs are fully integrated, likely by mid-2010, please visit www.PfizerHelpfulAnswers.com and click on the Wyeth link or call 866-706-2400 and ask for help with Wyeth medicines.

About Pfizer Helpful Answers®
Pfizer Helpful Answers is a family of patient assistance programs for the uninsured and underinsured who need help getting Pfizer medicines. Today, it is the largest and most extensive set of patient assistance programs in the United States. Pfizer Helpful Answers provides Pfizer medicines for free or at a savings to patients who qualify. Some programs also offer reimbursement support services for people with insurance. Pfizer Helpful Answers is a joint program of Pfizer Inc. and the Pfizer Patient Assistance Foundation™.

About Pfizer Inc.: Working together for a healthier world™
At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world’s leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at www.pfizer.com.

Most Popular Now

Cannabis extract helps reset brain function in psy…

Research from King's College London has found that a single dose of the cannabis extract cannabidiol can help reduce brain function abnormalities seen in people with psyc...

For first time in 40 years, cure for acute leukemi…

Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemi...

Consuming milk at breakfast lowers blood glucose t…

A change in breakfast routine may provide benefits for the management of type 2 diabetes, according to a new study published in the Journal of Dairy Science. H. Douglas G...

New cancer treatment uses enzymes to boost immune …

Researchers at The University of Texas at Austin have developed a new approach to treating cancer using enzyme therapy. The enzyme, PEG-KYNase, does not directly kill can...

Bayer accelerates six new startups

Changing the experience of health: that's the focus of the six startups which the Bayer G4A team has included in the Accelerator program this year. The young companies fr...

Novartis receives European Commission approval of …

Novartis today announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pe...

Shire completes sale of oncology franchise

Shire plc (LSE: SHP, NASDAQ: SHPG) announces today that it has completed the sale of its Oncology franchise to Servier S.A.S. for $2.4 billion. The franchise includes the...

Bristol-Myers Squibb - Pfizer Alliance ACROPOLIS™ …

The Bristol-Myers Squibb-Pfizer Alliance will present 15 Eliquis® (apixaban) posters at the ESC Congress 2018 held in Munich, Germany, August 25-29, 2018. Nine of the pos...

Antioxidant reduces risk for second heart attack, …

Doctors have long known that in the months after a heart attack or stroke, patients are more likely to have another attack or stroke. Now, a paper in the Journal of the A...

SOLAR-1 trial of Novartis investigational alpha-sp…

Novartis today announced the global Phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) has met the primary endpoint s...

Novartis to divest the Sandoz US dermatology busin…

Novartis today announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids po...

New tablet production facility in Ingelheim: Cente…

Boehringer Ingelheim held a groundbreaking ceremony for the construction of a new production facility for innovative drugs. This new Solids Launch facility will focus on ...